For Context:
# Abeona Therapeutics (NASDAQ: ABEO) reports FDA approval for Zevaskyn
ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure -
* Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile -
* ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025 -
* Abeona Assist™ patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN -
* Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA -
* Abeona Therapeutics® to host conference call today, Tuesday, April 29, 2025, at 8:00 a.m. ET -